IDiyas

For the Inventor, By the Inventor

Wuppertal, Germany

Thomas Neubauer

USPTO Granted Patents = 16 

 

Average Co-Inventor Count = 11.4

ph-index = 3

Forward Citations = 16(Granted Patents)


Company Filing History:

goldMedal15 out of 378 
 
Bayer Pharma Aktiengesellschaft
 patents
silverMedal6 out of 12,157 
 
Bayer Aktiengesellschaft
 patents
where one patent can have more than one assignee

Years Active: 2018-2023

Loading Chart...
Loading Chart...
16 patents (USPTO):
1. 11667675 - MASP inhibitory compounds and uses thereof (2023-06-06),
2. 11337973 - Substituted [1,2,4]triazolo[4,3-A]pyrazines as prolyl endopeptidase inhibitors (2022-05-24),
3. 11331314 - Amine substituted triazole derivatives and uses thereof (2022-05-17),
4. 11298367 - Prodrugs of substituted triazole derivatives and uses thereof (2022-04-12),
5. 11230540 - Substituted triazole derivatives and uses thereof (2022-01-25),
6. 11173151 - Substituted triazole derivatives and uses thereof (2021-11-16),
7. 11149023 - Substituted triazole derivatives and uses thereof (2021-10-19),
8. 11091463 - Amide-substituted pyridinyltriazole derivatives and uses thereof (2021-08-17),
9. 10927098 - Hydroxyalkyl-substituted triazole derivatives and uses thereof (2021-02-23),
10. 10815205 - Amide-substituted phenyltriazole derivatives and uses thereof (2020-10-27),
11. 10722501 - Substituted 5,6,7,8-tetrahydro[1,2,4]triazolo[4,3-A]pyridine-3(2H)-ones and 2,5,6,7-tetrahydro-3H-pyrrolo[2,1-C][1,2,4]triazol-3-ones, and use thereof (2020-07-28),
12. 10703742 - Method for producing 5-hydroxyalkyl-substituted 1-phenyl-1,2,4-triazole derivatives (2020-07-07),
13. 10526314 - Hydroxyalkyl-substituted heteroaryltriazole derivatives and uses thereof (2020-01-07),
14. 10525041 - Fluoroalkyl-substituted aryltriazole derivatives and uses thereof (2020-01-07),
15. 10472348 - Amide-substituted pyridinyltriazole derivatives and uses thereof (2019-11-12),

Title: Thomas Neubauer: Innovator in Medical Compounds

Introduction

Thomas Neubauer is a prominent inventor based in Wuppertal, Germany. He has made significant contributions to the field of medical research, particularly in the development of innovative compounds for treating various diseases. With a total of 16 patents to his name, Neubauer's work has the potential to impact the medical community profoundly.

Latest Patents

Among his latest patents is the invention of MASP inhibitory compounds and their uses. This invention relates to novel Mannose-binding lectin (MBL)-associated serine protease (MASP) inhibitory compounds, as well as analogues and derivatives. The patent outlines processes for the preparation of these compounds and their applications in treating and preventing diseases, particularly renal and cardiovascular disorders, as well as ischemia-reperfusion injuries. Another significant patent involves substituted [1,2,4]triazolo[4,3-A]pyrazines as prolyl endopeptidase inhibitors. This invention focuses on prolyl endopeptidase (PREP) inhibitors that contain a condensed 2,4-dihydro-3H-1,2,4-triazol-3-one ring system. The patent details methods for producing these inhibitors and their use in treating inflammatory lung diseases, such as Chronic Obstructive Pulmonary Disease (COPD).

Career Highlights

Throughout his career, Thomas Neubauer has worked with notable companies, including Bayer Pharma Aktiengesellschaft and Bayer Aktiengesellschaft. His experience in these organizations has allowed him to develop and refine his innovative ideas, contributing to advancements in medical treatments.

Collaborations

Neubauer has collaborated with esteemed colleagues, including Heiko Schirmer and Peter Kolkhof. These partnerships have fostered a collaborative environment that encourages the exchange of ideas and expertise in the field of medical research.

Conclusion

Thomas Neubauer's contributions to the field of medical innovation are noteworthy, with a focus on developing compounds that address critical health issues. His patents reflect a commitment to improving treatment options for various diseases, showcasing his role as a significant inventor in the medical community.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…